

November 15, 2022

David Southwell  
President and Chief Executive Officer  
TScan Therapeutics, Inc.  
830 Winter Street  
Waltham, Massachusetts 02451

Inc.

Statement on Form S-3

2022

Re: TScan Therapeutics,  
Registration  
Filed November 9,  
File No. 333-268260

Dear David Southwell:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Howes at 202-551-3370 with any questions.

Please contact Tyler

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:  
Esq.

William D. Collins,